Search

Displaying results 4301 - 4310 of 7059 in total
  1. Drug

    Furazolidone

    go.drugbank.com/drugs/DB00614
    InvestigationalVet approved

    A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  2. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. … It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.

  3. Drug

    PDPSC18

    go.drugbank.com/drugs/DB05167
    Experimental

    PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.

  4. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system. … plasma-derived FVIII, has been deleted and replaced by a 16 amino acid linker.

  5. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid … [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking

  6. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394] … Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).

  7. Drug

    VidPrevtyn Beta

    go.drugbank.com/drugs/DB16427
    Approved

    [A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691] … [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from

  8. Drug

    Lactitol

    go.drugbank.com/drugs/DB12942
    Approved

    Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. … [A190918] It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]).

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Taurolidine

    go.drugbank.com/drugs/DB12473
    ApprovedInvestigational

    It is a derivative of the amino acid [taurine]. … [A263217] In November 2023, a catheter lock solution of taurolidine in combination with [heparin] - marketed as Defencath - received FDA approval under the Limited Population Pathway for Antibacterial

  10. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    Sibeprenlimab is a Proliferation Inducing Ligand (APRIL) blocker.[L54633] APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells. … [A274848, A274853, A274858] Elevated APRIL levels are often observed in inflammatory disorders, including immunoglobulin A nephropathy (IgAN).